Inactive Instrument

Syneos Health, Inc.

SYNH

US87166B1026

Biotechnology & Medical Research

Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400

Published on 09/29/2023 at 12:00 am EDT

S&P Capital IQ

SYNEOS HEALTH, INC.

+0.02%

Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400

Latest news about Syneos Health, Inc.

May. 28	Syneos Health, Inc. Announces Appointment of Greg Licholai as Chief Medical Officer, Effective June 1, 2026	CI
May. 19	Helio Genomics And Syneos Health Enter Commercial Partnership To Accelerate Nationwide Adoption Of HelioLiver	CI
May. 14	Syneos Health Expands Strategic AI Partnerships	CI
May. 07	CausaLens and Syneos Health Expand Strategic Partnership to Scale Agentic AI in Biopharma Commercialization	CI
Apr. 30	Kai Conversations and Syneos Health Form Strategic Partnership to Advance U.S. Pharmaceutical Commercialization	CI
Mar. 20	Syneos Health, Inc. acquired Shanghai Bestudy Medical Technology Co., Ltd.	CI
Mar. 19	Big Bidders Reportedly Line Up for Nucleus Network	CI
Jan. 08	Syneos Health, Inc. Appoints Simon Bartle as Chief Human Resources Officer, Effective January 8, 2026	CI
25-10-21	Caremetx and Syneos Health Unite to Accelerate Patient Access	CI
24-10-09	Syneos Health Announces Chief Executive Officer Changes	CI
24-10-09	Syneos Health, Inc. Announces Board Appointments	CI
24-10-04	CytoDyn Inc. Engages Syneos Health as CRO for Its Phase II Oncology Trial	CI
23-10-03	Syneos Health Names Colin Shannon CEO	MT
23-10-03	Syneos Health, Inc. Announces Chief Executive Officer Changes	CI
23-09-29	Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400	CI

Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company's customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.

Employees

28,768

Sector

Biotechnology & Medical Research

More about the company